For investors seeking momentum, AGFiQ US Market Neutral Anti-Beta Fund (BTAL - Free Report) is probably on radar now. The fund just hit a 52-week high, which is up roughly 20.5% from its 52-week low price of $18.31/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
BTAL in Focus
The underlying Dow Jones U.S. Thematic Market Neutral Anti-Beta Index is a long/short market neutral index that is dollar-neutral. The fund charges 75 bps in fees (see all Long-Short ETFs here).
Why the Move?
Since markets have been volatile lately and there has been a bloodbath in the global market owing mainly to rising rate worries and concerns about waning global growth, this defensive ETF has gained strength.
More Gains Ahead?
The fund has a positive weighted alpha of 17.00. So, there is definitely still some promise for those who want to ride on this surging ETF a little longer, especially if uncertainty prevails.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For investors seeking momentum, AGFiQ US Market Neutral Anti-Beta Fund (BTAL - Free Report) is probably on radar now. The fund just hit a 52-week high, which is up roughly 20.5% from its 52-week low price of $18.31/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
BTAL in Focus
The underlying Dow Jones U.S. Thematic Market Neutral Anti-Beta Index is a long/short market neutral index that is dollar-neutral. The fund charges 75 bps in fees (see all Long-Short ETFs here).
Why the Move?
Since markets have been volatile lately and there has been a bloodbath in the global market owing mainly to rising rate worries and concerns about waning global growth, this defensive ETF has gained strength.
More Gains Ahead?
The fund has a positive weighted alpha of 17.00. So, there is definitely still some promise for those who want to ride on this surging ETF a little longer, especially if uncertainty prevails.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BTAL - FREE